日本がん対策新聞,
【結腸直腸がん】臨床病期Ⅱ−Ⅲにおける術前化学放射線療法の3年局所制御率：ゼローダ経口(11.8％)は、5−FU 持続静注(11.2%)と同等。〔J Natl Cancer Inst 2015〕 http://t.co/bYb8uPmQ9T
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
Overview of attention for article published in JNCI: Journal of the National Cancer Institute, September 2015
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (95th percentile)
-
High Attention Score compared to outputs of the same age and source (83rd percentile)
Mentioned by
- news
- 1 news outlet
- 7 X users
- 1 Facebook page
- guideline
- 8 clinical guideline sources
Readers on
- mendeley
- 213 Mendeley